Skip to main content
Withdrawn

A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies

By April 24, 2017No Comments

Condition

Cancer|Neoplasms|Tumors

Estimated Enrollment: 0

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: IRB00047570|WCI1895-10

Study First Received: December 20, 2011

Last Updated: November 19, 2013

Estimated Primary Completion Date: October 2013

 

Primary Outcome Measures:

Assessment of dose-limiting toxicity|Progression-free survival

Sponsors and Collaborators:

Emory University|OSI Pharmaceuticals

Website Link: https://ClinicalTrials.gov/show/NCT01567384

Leave a Reply